NCT04781192 2026-01-23The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract CancersUniversity of Kansas Medical CenterPhase 1/2 Active not recruiting40 enrolled